Trasylol side effects - The new Vioxx?
The lead author of the 2006 Trasylol side effects study published in the New England Journal of Medicine, Dr. Dennis Mangano, has stated that Trasylol problems occurred with greater frequency than those associated with the pain medication Vioxx. Dr. Mangano relates, "In fact our findings raise even more troubling concerns, for:
(1) aprotinin has been on the market for three times as long as Vioxx, yet few comprehensive safety studies have been conducted since approval;
(2) the life-threatening complications with aprotinin found here occurred far more frequently than those with Vioxx; and
(3) far less expensive generic alternatives to aprotinin which are equally effective in limiting bleeding have been available, but have been underused."
The observational Trasylol side effects study concluded, "Our findings raise serious concerns regarding the safety of an approved drug intended to limit blood loss in at-risk patients undergoing surgery." Mangano's opinion in respect to the future use of Trasylol was strongly worded: "In good conscience, I could not administer (Trasylol) to this group of patients, especially given the availability of safer alternatives." The FDA is reviewing current Trasylol side effects information and studies and advising doctors to consider limiting the medicine's use.
